Macrophage Fcγ receptors expression is altered by treatment with dopaminergic drugs

Clinical Immunology

Volumn 90, Issue 3, 1999, Pages 375-387

  Gomez, F ^a   Ruiz, P ^a   Briceno F ^a   Rivera, C ^a   Lopez, R ^a  

^a NONE

Author keywords

Dopaminergic drugs; Fc receptors; Macrophage

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ALIZAPRIDE; BROMOCRIPTINE; CHLORPROMAZINE; CISAPRIDE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; FC RECEPTOR; IMMUNOGLOBULIN G; LEUPRORELIN; METOCLOPRAMIDE; PERGOLIDE; SULPIRIDE; VERALIPRIDE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; GUINEA PIG; IMMUNOMODULATION; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN; ANIMAL; BIOSYNTHESIS; CLASSIFICATION; COMPARATIVE STUDY; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; IMMUNE COMPLEX DISEASE; IMMUNOLOGY; METABOLISM; NEUTROPENIA;

ANIMALS; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GUINEA PIGS; IMMUNE COMPLEX DISEASES; MACROPHAGES; MALE; NEUTROPENIA; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RECEPTORS, IGG; SPLEEN;

EID: 0032587897     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.1998.4665     Document Type: Article

References (63)

1. Ruiz, P., Gomez, F., and Schhreiber, A. D., Impaired macrophage Fcγ receptor function in chronic renal failure. N. Engl. J. Med. 322, 717-722, 1990.
2. Gomez, F., Ruiz, P., and Schreiber, A. D., Impairment of Fcγ-receptor predisposes to severe bacterial infection in alcoholic cirrhosis. N. Engl. J. Med. 331, 1122-1128, 1994.
3. Schreiber, A. D., and Frank, M. M., Role of antibody and complement in the immune clearance and destruction of erythrocytes. I. In vivo effects of IgG and IgM complement-fixing sites. J. Clin. Invest. 81, 575, 1972.
4. Schreiber, A. D., and Frank, M. M., Role of antibody and complement in the immune clearance and destruction of erythrocytes. II. Molecular nature of IgG and IgM complement-fixing sites and effects of their interaction with serum. J. Clin. Invest. 51, 583, 1972.
5. George, J. N., El-Harake, M. A., and Raskob, G. E., Chronic idiopathic thrombocytopenic purpura. N. Engl. J. Med. 331, 1207-1211, 1994.
6. Chaplin, H. Jr., Cohen, R., Bloomberg, G., Kaplan, H. J., Moore, J. A., and Dorner, I., Pregnancy and idiopathic autoimmune haemolytic anemia. A prospective study during 6 months gestation and 3 months post-partum. Br. J. Haematol. 24, 219, 1973.
7. Fehr, J., Hoffman, V., and Kappeler, U., Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high dose intravenous gammaglobulin. N. Engl. J. Med. 306, 1254-1258, 1982.
8. Schreiber, A. D., Nettl, F. M., Sanders, M. C., King, M., Szabolcs, P., Friedman, D., and Gomez, F., Effect of endogenous and synthetic sex steroids on the clearance of antibody-coated cells. J. Immunol. 141, 2959, 1988.
9. Ruiz, P., Gomez, F., King, M., Lopez, R., Darby, C., and Schreiber, A. D., In vivo glucocorticoid modulation of guinea pig splenic macrophage Fcγ receptors. J. Clin. Invest. 88, 149, 1991.
10. Debré, M., Bonnet, M.-C., Fridman, W.-H., Carosella, E., et al., Infusion of Fcγ fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 342, 945-949, 1993.
11. Reber, P. M., Prolactin and immunomodulation. Am. J. Med. 95, 637-644, 1993.
12. Brennan, Ollier, B., Worthington, J., Hajeer, A., and Silman, A., Are both genetic and reproductive associations with rheumatoid arthritis linked to prolactin? Lancet 348, 106-109, 1996.
13. Burlingame, R. W., and Rubin, R. L., Drug-induced anti-histone autoantibodies display two patterns of reactivity with substructures of chromatin. J. Clin. Invest. 88, 680-689, 1981.
14. Hess, E. V., Drug-related lupus. Curr. Opin. Rheumatol. 3, 809-817, 1991.
15. Quismorio, F. P., Bjarnason, D. F., and Kiely, W. F., Antinuclear antibodies in chronic psychotic patients treated with chlorpromazine. Am. J. Psychiatry, 132, 1204-1209, 1975.
16. Canoso, R. T., and de Oliveira, R. M., Chlorpromazine-induced anticardiolipin antibodies and lupus anticoagulant: Absence of thrombosis. Am. J. Hematol. 27, 272-278, 1988.
17. Zucker, S., Zarrabi, H. M., Schubach, W. H., Varma, A., Derman, R., Lysik, R. M., Habicht, G., and Seitz, P. M., Chlorpromazine-induced immunopathy: Progressive increase in serum IgM. Medicine 69, 92-103, 1990.
18. Gillilland, B. C., Drug-induced autoimmune and hematologic disorders. Drug Allergy 11, 525-538, 1991.
19. Rodebush, R. E., Berry, P. L., Layman, N. K., Butler, L. D., and Bryand, H. U., Dissociation of immunosuppression by chlorpromazine and trifluoperazine from pharmacological activities as dopamine antagonists. Int. J. Immunopharmacol. 13, 961-973, 1991.
20. Gadina, M., Bertini, R., Mengozzi, M., Zandalasini, M., Mantovania, A., and Ghezzi, P., Protective effect of chlorpromazine on endotoxin toxicity and TNF production in glucocorticoid-sensitive and glucocorticoid-resistant models of endotoxic shock. J. Exp. Med. 1733, 1305-1312, 1991.
21. Gomez, F., Ruiz, P., and Schreiber, A. D., A dopa antagonist inhibits receptor dependent immune clearance. Clin. Res. 42, 186A, 1994.
22. Mollloy, A. G., and Waddington, J. L., Sniffing, rearing and locomotor responses to the D-1 dopamine agonist R-SK F 38393 and to apomorphine: Differential interactions with the selective D-1 and D-2 antagonists SCH 23390 and metochhlopramide. Eur. J. Pharmacol. 108, 305-314, 1985.
23. Eilam, D., Golani, I., and Szechhtman, D2-anatonist quinpirole induces perseveration of routes and hyperactivity but not perseveration of movements. Brain Res. 490, 255-263, 1989.
24. Shimamura, T., Nakamura, T., and Koyama, J., Demonstration of the evidence of two distinct Fc receptors for IgG isotypes on guinea pig macrophages by the use of monoclonal antibodies. Mol. Immunol. 24, 67-74, 1987.
25. Wollters, E. C., Tissing, G., Bergmans, P. L., and Kampe, M. A., Dopamine agonist in Parkinson's disease. Neurology 45(3 Suppl. 3), S28-S34, 1995.
26. Session, D. R., Peralstone, M. M., Jewelevictz, R., and Kellly, A. C., Estrogens and Parkinson's disease. From theory to practice. Med. Hypotheses 42, 280-282, 1994.
27. Mizuno, Y., Kondo, T., and Narabayashi, H., Pergolide in the treatment of Parkinson's disease. Neurology 45(3 Suppl. 3), S13-S21, 1995.
28. Kane, J. M., Antipsychotic medication in the treatment of schizophrenia. Isr. J. Psychiatry Relat. Sci. 32, 30-37, 1995.
29. Orihata, M., and Saina, K., Contractile mechanisms of actions of grastroprokinetic agents. Am. J. Physiol. 266, 665-676, 1994.
30. Bianco, V., Colombo, A., and Tassan-Simonat, P., Climateric syndrome: Comparison of several secondary therapies. Ann. Obstet. Ginecol. Med. Perinat. 112, 54-60, 1991.
31. David, A., Don, R., Talchner, G., and Weissglas, L., Veralipride: Alternative antidopaminergic treatment for menopausal symptoms. Am. J. Obstet. Gynecol. 158, 1107-1115, 1988.
32. Seng, K. T., Tiong, C. E., and Hiang, T. C., Antiemetic effect of high-dose metochlopramide vs. alizapride, a randomized cross-over study. Br. J. Clin. Pharmacol. 38, 282-284, 1994.
33. Wiseman, L. R., and Fauds, D., Cisapride: An updated review of its pharmacologic and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs 47, 116-152, 1994.
34. Schreiner, G. F., and Unanue, E. R., Membrane and cytoplasmic changes in B lymphocytes induced by ligand-surface immunoglobulin alteration. Adv. Immunol. 31, 67-77, 1976.
35. Frank, M. M., Lawley, T. J., Hamburger, M. I., and Schreiber, A. D., NIH Conference: Immunoglobulin G Fc receptor-mediated clearance in autoimmune diseases. Ann. Intern. Med. 98, 206-217, 1979.
36. Hamburger, M. I., Lawley, T. J., Kimberly, R. P., Plotz, P. H., and Frank, M. M., A serial study of splenic reticuloendothelial system Fc receptor functional activity in systemic lupus erythhematosus. Arthritis Rheum. 25, 48-56, 1982.
37. Salmon, J. E., Kimberly, R. P., Gibofsky, A., and Fotino, M., Defective mononuclear phagocyte function in systemic lupus erythematosus: Dissociation of Fc receptor-ligand binding and internalization. J. Immunol. 133, 2525-2533, 1984.
38. Frank, M. M., Hamburger, M. I., Lawley, T. J., Kimberly, R. P., and Plotz, P. H., Defective reticuloendothelial system Fc-receptor function in systemic lupus erythematosus. N. Engl. J. Med. 300, 518-524, 1979.
39. Fields, T. R., Gerardi, E. N., Ghebrehiwet, B., Bennett, R. S., Lawley, T. J., Hall, R. P., et al., Reticuloendothelial system Fc receptor function in rheumatoid arthritis. J. Rheumatol. 10, 550-558, 1983.
40. Minuk, G. Y., Angus, M., Brickman, C. M., Lawley, T. J., Frank, M. M., Hoofnagle, J. H., and Jones, E. A., Abnormal clearance of immune complexes from the circulation of patients with primary sclerosing cholangitis. Gastroeneterology 88, 166-173, 1985.
41. Boros, P., Muryoi, T., Siera, H., Bona, C., and Unkeless, J. C., Autoantibodies directed against different classes of FcyR are found in sera of autoimmune patients. J. Immunol. 150, 2018-2024, 1993.
42. Kimberly, R. P., Salmon, J. E., Bussel, J. B., et al., Modulation of mononuclear phagocyte function by intravenous gammaglobulin. J. Immunol. 132, 745-750, 1984.
43. Blanchette, V., Imbach, P., Andrew, M., Adams, M., McMillan, J., et al., Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 344, 703-707, 1994.
44. Andersen, J. C., Response of resistant immune thrombocytopenic purpura to pulsed high-dose dexamethasone therapy. N. Engl. J. Med. 330, 1560-1564, 1994.
45. Doan, C. A., Bouroncle, B. A., and Wiseman, B. K., Idiopathic and secondary thrombocytopenic purpura: Clinical study and evaluation of 381 cases over a period of 28 years. Ann. Intern. Med. 53, 861-876, 1960.
46. Isakov, N., and Alman, A., Human T lymphocyte activation by tumor promoters: Role of protein kinase C. J. Immunol. 138, 3100-3107, 1987.
47. Hostetler, K. Y., and Matsuzawa, Y. H., Studies on the mechanisms of drug-induced lipolysis. Cationic amphiphilic drug inhibition of lysosomal phospholipases A and C. Biochem. Pharmacol. 30, 1121-1132, 1981.
48. Lee, T. P., Venuti, J., Kawauchi, R., Davis, P. J., and Mookerjee, B. K., Characteristics of calmodulin binding to purified human lymphocyte plasma membranes. J. Immunol. 1339, 42-54, 1987.
49. Ryan, G., Unanue, E., and Marnovsky, M., Inhibition of surface capping of macromolecules by local anaesthetics and tranquilizers. Nature 250, 56-58, 1974.
50. Llorente, L., Rchauddpatin, Y., Wijdenes, J., Alcocer-Varela, J., Maillo, M. C., Durand-Gasselin, I., Fourrier, B. M., Galanaudd, P., and Emilie, D., Spontaneous production of interleukin-10 by B lymphocytes and monocytes in systemic lupus eryhtematosus. Eur. Cytokine Network 4, 421-423, 1993.
51. Santambroglio, L., Lipartiti, M., Bruni, A., and Dal Toso, R., Dopamine receptors on human T- and B-lymphocytes. J. Neuroimmunol. 45, 113-119, 1993.
52. Takahasi, N., Nagai, Y., Veno, S., Saeki, Y., and Yanagihara, T., Human peripheral blood lymphocytes express D5 dopamine receptor gene and transcribe the two pseudogenes. FEBS Lett. 314, 23-25, 1992.
53. Verseke, K., Dhont, M., and Vandekerckhove, D., Clinical and hormonal effects of long-term veralipride treatment in postmenopausal women. Maturitas 10, 225-230, 1988.
54. Fioretti, P., Cagnacci, A., Paoletti, A. M., Gambacciani, M., et al., Effects of the antidopaminergic drug veralipride on LH and PRL secretion in postmenopausal women. J. Endocrinol. Invest. 12, 295-301, 1989.
55. David, A., Don, R., Tajchner, G., and Weissglas, L., Veralipride: Alternative antidopaminergic treatment for postmenopausal symptoms. Am. J. Obstet. Gynecol. 158, 1107-1115, 1988.
56. Melis, G. B., Gambacciani, M., Cagnacci, A., et al., Effects of the dopamine antagonist veralipride on hot flushes and luteinizing hormone secretion in postmenopausal women. Obstet. Gynecol. 72, 688-692, 1988.
57. Zichella, L., Flaschi, P., Fioretti, P., et al., Effect of different dopamine agonists and antagonists on postmenopausal hot flushes. Maturitas 8, 229-237, 1986.
58. Reichlin, S., Neuroendocrine-immune interactions. N. Engl. J. Med. 329, 1246-1253, 1993.
59. Ader, R., Cohen, N., and Felten, D., Psychoneuroimmunology: Interactions between the nervous system and the immune system. Lancet 345, 99-103, 1995.
60. Boros, P., Bona, C., and Unkeless, J. C., The role of Fc gamma receptors in autoimmunity. In "The Molecular Pathology of Autoimmune Diseases" (C. Bona, K. Siminovitch, M. Zanetti, and A. N. Theophilopoulos, Eds.), p. 191, Harwood Academic Publishers, Chur, Switzerland, 1993.
61. Forges, A. J., Redecha, P. B., Kimberley, W. T., Csernok, E., Gross, W. L., and Kimberley, R. P., Anti-neutrophil cytoplasmic antibodies engage and activate human neutrophil via FcγRIIa. J. Immunol. 153, 1271-1280, 1994.
62. Boros, P., Chen, J., Bona, C., and Unkeless, J. C., Autoimmune mice make anti-Fc gamma receptor Ig. J. Exp. Med. 171, 1581-1590, 1990.
63. Boros, P., Odin, J. A., Muryoi, T., Masur, S. K., Bona, C., and Unkeless, J. C., IgM anti-FcγR autoantibodies trigger neutrophil degranulation. J. Exp. Med. 173, 1473-1485, 1991.